CONFORMED
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
___________________
Date of Report (Date of earliest event reported) March 22, 1996
BIOCONTROL TECHNOLOGY, INC.
(Exact name of registrant as specified in its charter)
Pennsylvania 0-10822 25-1229323
(State of other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification no.)
300 Indian Springs Road, Indiana, Pennsylvania 15701
(Address of principal executive offices) ( Zip Code)
Registrant's telephone number, including area code (412) 349-1811
_________________________________________________________________
(Former name or former address, if changes since last report.)
<PAGE>
Item 1. Change in Control of Registrant.
Not applicable.
Item 2. Acquisition or Disposition of Assets.
Not applicable.
Item 3. Bankruptcy or Receivership.
Not applicable.
Item 4. Changes in Registrant's Certifying Accountant
Not applicable.
Item 5. Other Events.
On March 22, 1996, Biocontrol Technology, Inc. announced that The
Food and Drug Administration (FDA) recently responded to the
February 26, 1996 panel review of the Company's Diasensor 1000
(noninvasive glucose sensor by requesting BICo to submit a study
design for collecting additional data on the Diasensor 1000)
production model. The Company is communicating with the FDA on
the matter.
Biocontrol also announced that four production models are now complete.
The three most recently produced units are undergoing laboratory tests
while successful calibration has been achieved on the first unit
produced which has generated very encouraging data during testing
of several patients.
Assembly of 30 additional production models will commence the first
week of April at Biocontrol's Manufacturing Center in Indiana, PA.
By early May, the Company anticipates having all 30 units completed,
20 of which will be field tested on patients. The remaining ten
units will be studied by Biocontrol scientists for possible areas
of improvement.
Once the field tests on the 20 units have been successfully completed,
Biocontrol will begin shipment to the London office for sales there
while the Company continues its approval process with the US FDA.
Item 6. Resignation of Registrant's Directors.
Not Applicable
Item 7. Financial Statement, Pro Forma Financial Information and Exhibits.
(a) Financial Statements and Businesses Acquired - Not Applicable.
(b) Pro Forma Financial Information - Not Applicable.
(c) Exhibits - News Release
<PAGE>
SIGNATURES
Pursuant to the requirement of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
BIOCONTROL TECHNOLOGY, INC.
by /s/ Fred E. Cooper
Fred E. Cooper, CEO
DATED: March 22, 1996
